Catalyst Financial Partners LLC Has $2.55 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Catalyst Financial Partners LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 2.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,368 shares of the company’s stock after acquiring an additional 85 shares during the period. Eli Lilly and Company comprises 0.7% of Catalyst Financial Partners LLC’s holdings, making the stock its 24th biggest position. Catalyst Financial Partners LLC’s holdings in Eli Lilly and Company were worth $2,546,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the 3rd quarter valued at about $27,000. Optiver Holding B.V. bought a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $36,000. Family CFO Inc purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth about $40,000. Finally, O Brien Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 70.5% during the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 0.4 %

Shares of NYSE:LLY traded down $3.45 during trading on Thursday, reaching $771.55. 2,317,073 shares of the company were exchanged, compared to its average volume of 3,068,803. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The firm has a market capitalization of $733.28 billion, a PE ratio of 113.63, a P/E/G ratio of 1.45 and a beta of 0.37. The business’s fifty day simple moving average is $761.56 and its 200-day simple moving average is $675.58. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the company posted $1.62 EPS. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. On average, research analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be given a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. Eli Lilly and Company’s payout ratio is 76.58%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on LLY shares. The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. BMO Capital Markets increased their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, Citigroup increased their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.